- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06822426
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults And Adolescent Participants Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
A Phase 3, Prospective, Multicenter, Double-Blind, Randomized, Controlled, Adaptive Study To Demonstrate The Safety And Efficacy Of DEFENCATH® In Reducing Central Line-Associated Bloodstream Infections (CLABSIs) In Adult And Adolescent Participants Receiving Total Parenteral Nutrition (TPN) Via Central Venous Catheter (CVC)
This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult and adolescent participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.
Studieoversigt
Status
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Udvidet adgang
Kontakter og lokationer
Studiekontakt
- Navn: Liz Hurlburt, Chief Clinical Strategy & Operations Officer
- Telefonnummer: 908-517-9500
- E-mail: lhurlburt@cormedix.com
Studiesteder
-
-
California
-
Los Angeles, California, Forenede Stater, 90024
- Rekruttering
- University of California Los Angeles
-
Kontakt:
- Michael C Garcia, MD
- Telefonnummer: 310-206-1987
- E-mail: mcgarcia@mednet.ucla.edu
-
Kontakt:
- Jeraldine Guzman
- Telefonnummer: 310.206.8292
- E-mail: Jbguzman@mednet.ucla.edu
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- Rekruttering
- MedStar Health Research Institute
-
Kontakt:
- Jeffrey Shupp, MD
- Telefonnummer: 202-877-5133
- E-mail: jeffrey.w.shupp@medstar.net
-
Kontakt:
- Alison Ross
- Telefonnummer: 202-877-5170
- E-mail: fbsrlresearch@medstar.net
-
-
Florida
-
Doral, Florida, Forenede Stater, 33122
- Rekruttering
- Bioresearch Partner
-
Kontakt:
- Rafael Abreu, MD
- Telefonnummer: 833-489-4968
- E-mail: rabreumd@bioresearchpartner.com
-
Kontakt:
- Keila Hoover
- Telefonnummer: 833-489-4868
- E-mail: khoovermd@bioresearchpartner.com
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30322
- Rekruttering
- Emory University Hospital - GCRC
-
Kontakt:
- Thomas R Ziegler, MD
- Telefonnummer: 404-727-7351
- E-mail: tzieg01@emory.edu
-
Kontakt:
- Xu Wang
- E-mail: xwang39@emory.edu
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- University of Chicago Medical Center
-
Kontakt:
- Carol Semrad, MD
- Telefonnummer: 773-702-6921
- E-mail: csemrad@bsd.uchicago.edu
-
Kontakt:
- Kristi Kearney
- Telefonnummer: 773-834-7414
- E-mail: kristi.kearney@uchicagomedicine.org
-
Maywood, Illinois, Forenede Stater, 60153
- Rekruttering
- Loyola University Medical Center
-
Kontakt:
- Dejan Micic, MD
- Telefonnummer: 888-584-7888
- E-mail: dejan.micic@lumc.edu
-
Kontakt:
- Maria Chavez
- Telefonnummer: 464-220-9498
- E-mail: mchavez11@luc.edu
-
-
Iowa
-
Iowa City, Iowa, Forenede Stater, 52242
- Rekruttering
- University of Iowa Health Care
-
Kontakt:
- Ethan Hoover, RN, MNHP
- Telefonnummer: 319-335-9767
- E-mail: ethan-hoover@uiowa.edu
-
Kontakt:
- Divya Ashat, MD
- Telefonnummer: 319-384-5492
- E-mail: divya-ashat@uiowa.edu
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21205
- Rekruttering
- Johns Hopkins Clinical Research Unit
-
Kontakt:
- Sara Keller, MD, MPH, MSHP
- Telefonnummer: 410-952-7572
- E-mail: Skeller9@jhmi.edu
-
Kontakt:
- Marwa El-Ashry, BS
- Telefonnummer: 667-306-9370
- E-mail: melashr1@jh.edu
-
-
Minnesota
-
Rochester, Minnesota, Forenede Stater, 55905
- Rekruttering
- Mayo Clinic
-
Kontakt:
- Bradley Salonen, MD
- Telefonnummer: 507-284-4805
- E-mail: Salonen.Bradley@mayo.edu
-
Kontakt:
- Pearl Buabeng
- E-mail: Buabeng.Pearl@mayo.edu
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68198-3285
- Rekruttering
- University of Nebraska Medical Center
-
Kontakt:
- David F Mercer, MD, PhD, FRCS(C)
- Telefonnummer: 402-559-6955
- E-mail: dmercer@unmc.edu
-
Kontakt:
- Rachel Harper, RN, BSN
- Telefonnummer: 402-559-1282
- E-mail: raharper@unmc.edu
-
-
New York
-
New York, New York, Forenede Stater, 10032
- Rekruttering
- Columbia University Irving Medical Center
-
Kontakt:
- Michael Owen-Michaane, MD
- Telefonnummer: 212-342-3881
- E-mail: mco2125@cumc.columbia.edu
-
Kontakt:
- Brett Gray, ANP, MPH
- Telefonnummer: 212-305-1570
- E-mail: bg2168@cumc.columbia.edu
-
New York, New York, Forenede Stater, 10029
- Rekruttering
- Mount Sinai Medical Center
-
Kontakt:
- Kishore Iyer, MD
- Telefonnummer: 212-241-2064
- E-mail: kishore.iyer@mountsinai.org
-
Kontakt:
- Brandy Haydel
- Telefonnummer: 212-241-0255
- E-mail: brandy.haydel@mountsinai.org
-
New York, New York, Forenede Stater, 10016
- Ikke rekrutterer endnu
- NYU Grossman School of Medicine
-
Kontakt:
- Jennifer Katz, MD
- Telefonnummer: 212-263-3643
- E-mail: jennifer.katz@nyulangone.org
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27710
- Trukket tilbage
- Duke University Hospital
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Rekruttering
- Cleveland Clinic Foundation
-
Kontakt:
- Cynthia Stokes
- E-mail: stokesc2@ccf.org
-
Kontakt:
- Jessica Sosio, DO
- Telefonnummer: 216-442-2416
- E-mail: sosioj@ccf.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- Rekruttering
- Hospital of the University of Pennsylvania
-
Kontakt:
- Valerianna Amorosa, MD
- Telefonnummer: 215-873-4998
- E-mail: Valerianna.Amorosa@pennmedicine.upenn.edu
-
Kontakt:
- Kelly Wall
- E-mail: kelly.wall@pennmedicine.upenn.edu
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02903
- Rekruttering
- Rhode Island Hospital
-
Kontakt:
- Benjamin Hall, MD
- Telefonnummer: 401-444-4296
- E-mail: benjamin_hall@brown.edu
-
Kontakt:
- Marion Winkler, PhD, RD, LDN, CNSC
- Telefonnummer: 401-444-4276
- E-mail: mwinkler@brownhealth.org
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37212-1150
- Rekruttering
- Vanderbilt Center for Human Nutrition
-
Kontakt:
- Dawn Adams, MD
- Telefonnummer: 615-936-0192
- E-mail: dawn.w.adams@vumc.org
-
Kontakt:
- Sean Durkin, BS
- Telefonnummer: 615-343-4216
- E-mail: sean.durkin@vumc.org
-
-
Texas
-
Sugarland, Texas, Forenede Stater, 77478
- Rekruttering
- Alchemi - Sugarland
-
Kontakt:
- Olumayowa Aderinto, MD
- Telefonnummer: 346- 673-1322
- E-mail: o.aderintomd@alchemirc.com
-
Kontakt:
- Kenneth Morgan, MSc
- Telefonnummer: 832-307-3100
- E-mail: k.morgan@alchemirc.com
-
-
-
-
Ankara
-
Altındağ, Ankara, Tyrkiet (Türkiye), 06230
- Rekruttering
- Hacettepe University Hospitals
-
Kontakt:
- Prof. Dr. Meltem Gulhan Halil
- Telefonnummer: (90) 532 786 45 35
- E-mail: meltemhalil@yahoo.com
-
Kontakt:
- Fatma Tamer
- Telefonnummer: (90) 533 339 18 11
- E-mail: fatmatamer06@gmail.com
-
Yenimahalle, Ankara, Tyrkiet (Türkiye), 06560
- Rekruttering
- Hacettepe University Hospitals
-
Kontakt:
- Prof. Dr. Melda Türkoğlu
- Telefonnummer: (90) 532 523 38 10
- E-mail: meldaturkoglu@yahoo.com
-
Kontakt:
- Assoc. Prof. Dr. Kamil Inci
- Telefonnummer: (90) 544 212 25 45
- E-mail: kamilinci@gmail.com
-
Çankaya, Ankara, Tyrkiet (Türkiye), 06800
- Rekruttering
- Ankara Bilkent City Hospital
-
Kontakt:
- Prof. Dr. Mutlu Doganay
- Telefonnummer: (90) 532 295 60 50
- E-mail: drmdoganay@gmail.com
-
Kontakt:
- Dr. Piril Tuncay
- Telefonnummer: (90) 505 386 90 32
- E-mail: piril_tuncay@hotmail.com
-
Çankaya, Ankara, Tyrkiet (Türkiye), 06230
- Rekruttering
- Ankara University Ibni Sina Research and Application Hospital
-
Kontakt:
- Prof. Dr. Seher Demirer
- Telefonnummer: (90) 532 569 27 12
- E-mail: seher.demirer@gmail.com
-
Kontakt:
- Dr. Süleyman Utku Çelik
- Telefonnummer: (90) 535 339 16 50
- E-mail: s.utkucelik@hotmail.com
-
-
Istanbul
-
Istanbul, Istanbul, Tyrkiet (Türkiye), 34093
- Rekruttering
- Istanbul University Faculty of Medicine, Capa State Hospital
-
Kontakt:
- Prof. Dr. Bulent Saka
- Telefonnummer: (90) 532 366 65 41
- E-mail: bulent.saka@istanbul.edu.tr
-
Kontakt:
- Assoc. Prof. Dr. Mustafa Altinkaynak
- Telefonnummer: (90) 506 658 15 97
- E-mail: mustafa.altinkaynak@istanbul.edu.tr
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
-
Participants who are resident within study site's country.
-
Participants who are male or female, aged ≥12 years at the time of consent.
-
Participants must sign and provide informed consent. For adolescent participants or participants that require a legal representative, written informed consent will be obtained from the study participant's legal guardian or legal representative and the assent from the participant when applicable. All legal guardians and representatives should be fully informed, and participants should be informed to the fullest extent possible about the study using language and terms they are able to understand.
-
Participants who have a tunneled/non-tunneled CVC or peripherally inserted central catheter (PICC) made of silicone or polyurethane, which has been in place for at least 7 days prior to enrollment.
-
Participants who require long-term (>3 Months) TPN based on the investigator assessments.
-
Participants who require TPN for at least 3 days per week, of which 2 days have to be parenteral nutrition (PN).
-
Participants who have a minimum of a 4-hour CLS dwelling time and are willing to lock all lumens at a minimum of every 7 days.
-
Participants who are clinically stable, in the opinion of the investigator, for at least 4 weeks prior to enrollment.
-
Participants who are able and willing to be trained or have a caregiver who is willing and able to be trained on the instillation, aspiration of DefenCath or heparin, and to maintain a daily diary.
Male or female participants:
-
Women of childbearing potential (WOCBP; see Section 4.5.1) must have a negative pregnancy test at screening (i.e., the participant is not pregnant); not be lactating; and use an acceptable method of contraception including but not limited to, abstinence, bilateral tubal ligation, vasectomized partner, a barrier method (diaphragm or condom), Depo-Provera, intrauterine device, or hormonal contraceptive (oral, implant, ring, patch) for the duration of the program until at least 30 days after the last DefenCath CLS instillation. (NOTE: The participant must have used the chosen method of birth control for at least 1 month/cycle prior to enrollment into the study).
-
Male participants who are sexually active with a female partner of childbearing potential must agree to use male condoms with spermicide, even if the male participant has undergone a successful vasectomy (males with vasectomy can use condoms without spermicide), from Day 1 until at least 30 days after the last DefenCath CLS instillation.
-
Participants who comply with all study procedures and follow-up evaluations.
Exclusion Criteria:
- Any participant unable or not willing to sign inform consent or, in the case of adolescents, not willing to provide assent.
- Any participant who is currently receiving systemic antibiotics. Topical antibiotics are permitted. Use of metronidazole or rifaximin for treating small intestinal bacterial overgrowth (SIBO) is also permitted.
- Any participant with visible evidence of compromised skin integrity present at the catheter exist site or catheter exit site infection.
- Any participant with a secondary CVC in addition to the primary TPN line.
- Any participant that has received thrombolytic treatment (e.g., tissue-type plasminogen activator [tPA]-Cathflo), not as a part of the institution's standard of care for patency management, in current catheter within 30 days of randomization.
- Any participant with unstable arrhythmia, defined as presence of hemodynamic instability within a month prior to the baseline assessment.
- Any participant using any type of antimicrobial-coated or heparin-coated catheter.
- Any participant with documented chronic bleeding diathesis, active or recurrent bleeding within 1 month prior to randomization.
- Any participant with a congenitally lethal condition or a life expectancy of less than 6 months.
- Any participant with documented history of an atrial thrombus or known hypercoagulable state.
- Any participant with an open, non-healing skin ulcer.
- Any participant who has received an allogeneic hematopoietic stem cell transplant within the last year.
- Any participant with neutropenia with an absolute neutrophil count <500 cells/μL
- Any participant with current requirement for systemic chemotherapy and or immunosuppression and absolute neutrophil count <500 cells/μL that occured in the past 4 weeks.
- Any participant with known allergies or absolute contraindications to citrate, taurolidine, pork products, or heparin or a history of heparin-induced thrombocytopenia.
- Any participant taking other medication with known systemic drug interaction with citrate, taurolidine or heparin.
- Any participant anticipating receiving an intestinal transplant within 90 days. Participants can be on a transplant list but a participant with a known or anticipated transplant date within 90 days of study entry should be excluded from study participation. A participant who may receive an intestinal transplant >90 days of study entry may remain on the study as long as they continue to receive TPN.
- Any participant who is pregnant or lactating.
- Any participant receiving continuous TPN (infusion over 24 hours).
- Any participant with any medical conditions that render them unable to, or unlikely to complete the study or would interfere with optimal participation in the study or produce significant risk to participant.
- Any participants who are participating in another interventional clinical study or planning/anticipating participating in another interventional clinical study, except for non-pharmacological research studies.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Tredobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Styring
|
Heparin |
|
Eksperimentel: DefenCath®
|
for central venous catheter installation use |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Comparison between treatment groups of proportion of participants who experience a Central Line-Associated Bloodstream Infections (CLABSI) within 12 months of the start of the study
Tidsramme: Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
|
The proportion of participants who remain infection-free in the treatment groups will be compared, censoring participants who do not experience a CLABSI, but fail to complete the 12-month follow-up period of the study. |
Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of AEs, SAEs, treatment-emergent adverse events (TEAEs)
Tidsramme: Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
|
Compare the safety profile of DefenCath for use as a Catheter Lock Solution (CLS) in adult and adolescent participants receiving Total Parenteral Nutrition (TPN) through a Central Venous Catheter (CVC) to the control of heparin CLS |
Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
|
|
Incidence of changes in laboratory evaluations, vital signs, or physical exam findings
Tidsramme: Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
|
Compare the safety profile of DefenCath for use as a CLS in adult and adolescent participants receiving TPN through a CVC to the control of heparin CLS |
Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- NUTRI-GUARD
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Sharibg if protocol and ICF, pending FDA approval of this indication
IPD-delingstidsramme
Pending FDA Approval
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- ICF
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .